Status:
COMPLETED
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
APOL1-mediated Kidney Disease
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and PK of single and multiple ascending doses of VX-840 in healthy participants.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Key
- Female participants must be of non-childbearing potential
- Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m\^2)
- A total body weight greater than (\>) 50 kg
- Key
Exclusion
- History of febrile illness or other acute illness within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
April 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2022
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT05324410
Start Date
April 7 2022
End Date
November 7 2022
Last Update
December 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICON Lenexa
Lenexa, Kansas, United States, 66219